Literature DB >> 17802921

Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.

Gian Maria Rossolini1, Elisabetta Mantengoli, Jean-Denis Docquier, Rosa Anna Musmanno, Grazietta Coratza.   

Abstract

Microbial drug resistance is a growing problem of global magnitude. In gram-negative pathogens, the most important resistance problems are encountered in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter, with increasing trends observed for all major anti-gram-negative agents (beta-lactams, fluoroquinolones and aminoglycosides). A matter of major concern is the emergence of new beta-lactamases capable of degrading the expanded-spectrum cephalosporins and/or carbapenems, such as the extended-spectrum beta-lactamases (ESBLs) and the carbapenemases. These beta-lactamase genes are often associated with resistance determinants to non-beta-lactam agents (e.g. aminoglycosides and fluoroquinolones), and strains producing ESBLs or carbapenemases often exhibit complex multidrug resistant phenotypes and sometimes are panresistant. The problem is worsened by the dearth of new agents active on multidrug-resistant Gram-negatives in the pipeline. The importance to develop better strategies to control resistance is underscored.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17802921

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  18 in total

1.  Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments.

Authors:  A Vieira; Y J Silva; A Cunha; N C M Gomes; H-W Ackermann; A Almeida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-10       Impact factor: 3.267

2.  Nosocomial outbreak of VIM-1-producing Klebsiella pneumoniae isolates of multilocus sequence type 15: molecular basis, clinical risk factors, and outcome.

Authors:  Isabel Sánchez-Romero; Angel Asensio; Jesús Oteo; María Muñoz-Algarra; Beatriz Isidoro; Ana Vindel; José Alvarez-Avello; Bárbara Balandín-Moreno; Oscar Cuevas; Sara Fernández-Romero; Luisa Azañedo; David Sáez; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

3.  Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.

Authors:  John S Esterly; Milena Griffith; Chao Qi; Michael Malczynski; Michael J Postelnick; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

4.  Adaptive Responses of Pseudomonas aeruginosa to Treatment with Antibiotics.

Authors:  Dominik Wüllner; Maren Gesper; Annika Haupt; Xiaofei Liang; Pei Zhou; Pascal Dietze; Franz Narberhaus; Julia E Bandow
Journal:  Antimicrob Agents Chemother       Date:  2021-11-08       Impact factor: 5.938

5.  Modified CLSI extended-spectrum β-lactamase (ESBL) confirmatory test for phenotypic detection of ESBLs among Enterobacteriaceae producing various β-lactamases.

Authors:  Aggeliki Poulou; Evgenia Grivakou; Georgia Vrioni; Vassiliki Koumaki; Theodoros Pittaras; Spyros Pournaras; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2014-02-26       Impact factor: 5.948

6.  Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli.

Authors:  Rodrigo E Mendes; M R K Alley; Helio S Sader; Douglas J Biedenbach; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

7.  VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.

Authors:  Jose-Manuel Rodriguez-Martinez; Patrice Nordmann; Nicolas Fortineau; Laurent Poirel
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

8.  To study the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury associated with parenteral polymyxin B.

Authors:  Ruchika Nandha; Kavita Sekhri; Amit Kumar Mandal
Journal:  Indian J Crit Care Med       Date:  2013-09

9.  Access to antibiotics: a safety and equity challenge for the next decade.

Authors:  Jean Carlet; Didier Pittet
Journal:  Antimicrob Resist Infect Control       Date:  2013-01-10       Impact factor: 4.887

Review 10.  Strategies to minimize antibiotic resistance.

Authors:  Chang-Ro Lee; Ill Hwan Cho; Byeong Chul Jeong; Sang Hee Lee
Journal:  Int J Environ Res Public Health       Date:  2013-09-12       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.